Altered-Function p53 Missense Mutations Identified in Breast Cancers Can Have Subtle Effects on Transactivation
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Mutations of the sequence-specific master regulator p53 that alter transactivation function from promoter response elements (RE) could result in changes in the strength of gene activation or spectra of genes regulated. Such mutations in this tumor suppressor might lead to dramatic phenotypic changes and diversification of cell responses to stress. We have determined “functional fingerprints” of sporadic breast cancer–related p53 mutants, many of which are also associated with familial cancer proneness such as the Li-Fraumeni syndrome and germline BRCA1/2 mutant-associated cancers. The ability of p53, wild-type and mutants, to transactivate from 11 human target REs has been assessed at variable expression levels using a cellular, isogenomic yeast model system that allows for the rapid analysis of p53 function using a qualitative and a quantitative reporter. Among 50 missense mutants, 29 were classified as loss of function. The remaining 21 retained transactivation toward at least one RE. At high levels of galactose-induced p53 expression, 12 of 21 mutants that retain transactivation seemed similar to wild-type. When the level of galactose was reduced, transactivation defects could be revealed, suggesting that some breast cancer–related mutants can have subtle changes in transcription. These findings have been compared with clinical data from an ongoing neoadjuvant chemotherapy treatment trial for locally advanced breast tumors. The functional and nonfunctional missense mutations may distinguish tumors in terms of demographics, appearance, and relapse, implying that heterogeneity in the functionality of specific p53 mutations could affect clinical behavior and outcome. Mol Cancer Res; 8(5); 701–16. ©2010 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 1×
“The DBD of p53 consists of a β-sandwich, which provides a scaffold for two large β-loops, L2 and L3, which are stabilized by a zinc ion and a loop-sheet-helix motif (44, 45).”
BackgroundThe p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 7×
“Interestingly, p53 is unique in comparison with other transcription factors in that >75% of mutations that occur in this tumor suppressor are single amino acid changes that result in missense mutations (7).”
BackgroundMethodInfluentialMutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · cited 2×
“Recent results with knock-in mouse models indicate that levels of mutant p53 can be regulated in both normal and some tumor cells (59, 60).”
BackgroundGain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069 · cited 2×
“Recent results with knock-in mouse models indicate that levels of mutant p53 can be regulated in both normal and some tumor cells (59, 60).”
Backgroundp53 isoforms can regulate p53 transcriptional activity
Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., & Lane, D. P. (2005) · Genes & Development · doi:10.1101/gad.1339905 · Cited by 810 · cited 2×
“For example, similar to the p53 family members p63 and p73, specific p53 isoforms can influence promoter selection or functionality from specific REs through either synergistic or antagonistic mechanisms (78, 79).”
BackgroundEspinosa, J. M., Verdun, R. E., & Emerson, B. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00359-9 · Cited by 256 · cited 1×
“(63) observed that p53 occupies some target REs, including p21, before overall p53 stabilization.”
BackgroundUbiquitination and Degradation of Mutant p53
Lukashchuk, N., & Vousden, K. H. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00050-07 · Cited by 223
Resnick, M. A., & Inga, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633803100 · Cited by 149
Self-citationNoncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53
Jordan, J. J., Menendez, D., Inga, A., Nourredine, M., Bell, D., & Resnick, M. A. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000104 · Cited by 103 · cited 6×
“levels of galactose allow for >150-fold induction in protein expression (4).”
BackgroundMethodInfluentialSelf-citation
Cited by
Skinner, H. D., Sandulache, V. C., Ow, T. J., Meyn, R. E., Yordy, J. S., Beadle, B. M., Fitzgerald, A. L., Giri, U., Ang, K. K., & Myers, J. N. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2260 · Cited by 293
The rebel angel: mutant p53 as the driving oncogene in breast cancer
Walerych, D., Napoli, M., Collavin, L., & Del Sal, G. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs232 · Cited by 289
Shatz, M., Menendez, D., & Resnick, M. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4134 · Cited by 143
“Included is a brief description of the functional transactivation status for each p53 mutant based on yeast reporter assays (37, 38).”
Self-citationCoutant, C., Rouzier, R., Qi, Y., Lehmann-Che, J., Bianchini, G., Iwamoto, T., Hortobagyi, G. N., Symmans, W. F., Uzan, S., Andre, F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1045 · Cited by 64
“Jordan and colleagues have recently showed that the functional and nonfunctional missense mutations may distinguish tumors, implying that heterogeneity in the functionality of specific p53mutations could affect clinical behavior and outcome (21).”
Dutta, A. K., Alberge, J.-B., Lightbody, E. D., Boehner, C. J., Dunford, A., Sklavenitis-Pistofidis, R., Mouhieddine, T. H., Cowan, A. N., Su, N. K., Horowitz, E. M., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0482 · Cited by 41
Metadata
- Authors
- Jordan, J. J., Inga, A., Conway, K., Edmiston, S., Carey, L. A., Wu, L., & Resnick, M. A.
- Venue
- Molecular Cancer Research
- Published
- 2010-05-01
- Volume
- 8
- Issue
- 5
- Pages
- 701-716
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- OpenAlex
- W2158224935
- Cited by
- 77
- References
- 13
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Altered-Function p53 Missense Mutations Identified in Breast Cancers Can Have Subtle Effects on Transactivation. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-09-0442
- The paper
- Jordan, J. J., Inga, A., Conway, K., Edmiston, S., Carey, L. A., Wu, L., & Resnick, M. A. (2010). Altered-Function p53 Missense Mutations Identified in Breast Cancers Can Have Subtle Effects on Transactivation. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-09-0442
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.